货号 | AF6278-SP |
别名 | EC 3.4.19.3; PAP-I; Pcp; PGPIFLJ20208; PGP-IPAP-I; PGPMGC10812; Pyroglutamyl aminopeptidase I; pyroglutamyl-peptidase 1; pyroglutamyl-peptidase I5-oxoprolyl-peptidase; Pyrrolidone-carboxylate peptidase | 全称 | Pyroglutamyl Aminopeptidase I |
反应种属 | Human/Mouse |
应用 | Western Blot(1 µg/mL) |
目标/特异性 | Detects human PGPEP-1 in direct ELISAs and, human and mouse PGPEP-1 in Western blots. |
使用方法 | Western Blot: 1 µg/mL |
来源 | Sterile PBS to a final concentration of 0.2 mg/mL. |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 54858 (Human) |
纯化方式 | Antigen Affinity-purified |
免疫原 | E. coli-derived recombinant human PGPEP-1 Met1-His209 Accession # Q9NXJ5 |
生物活性 | Human, Mouse |
标记 | Unconjugated |
溶解方法 | Sterile PBS to a final concentration of 0.2 mg/mL. |
背景 | Pyroglutamyl peptidase-1 (PGPEP-1) is an omega peptidase which removes pyroglutamyl residues from the amino termini of peptides and proteins (1). It is a cytosolic cysteine peptidase that is expressed in most cell types (2). The enzyme requires a thiol‑reducing agent for activity (3). PGPEP-1 is potentially involved in the inactivation of biologically active peptides that possess an amino terminal pyroglutamyl group (3). Examples of such peptides include neurotensin, luteinizing hormone releasing hormone, and thyrotropin-releasing hormone. Human and mouse PGPEP-1 share 95% aa sequence identity. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Detection of Human and Mouse PGPEP‑1 by Western Blot. Western blot shows lysates of LNCaP human prostate cancer cell line, JAR human choriocarcinoma cell line, NTera‑2 human testicular embryonic carcinoma cell line, Neuro‑2A mouse neuroblastoma cell line, and human brain (cortex) tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human PGPEP‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6278) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for PGPEP‑1 at approximately 23 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. |